http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007066230-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d1b174da24b0ff2e1fa83412127905f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cfe88eeff887b43293a8ded60b0f473b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2bcaf91101a370a3d64e3190366357f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 |
| filingDate | 2006-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b48b999d1188d4b429626a52e2ebcf50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_335285184d326775492d8716f3fbe93e |
| publicationDate | 2007-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007066230-A2 |
| titleOfInvention | Method for identifying, marking and treating epithelial lung tumour cells and means for carrying out said method |
| abstract | The bronchial carcinoma is the most common tumour found in humans world-wide and is in most cases beyond remedy. The invention relates to a method for identifying, marking and treating epithelial lung tumour cells, specifically of an adenocarcinoma, with the aid of novel treatment targets, and to means for carrying out said method. At the basis of the invention is the discovery that the expression of genes that code for CAM and ECM molecules is modified in c-raf and/or c-myc induced adenocarcinomas of the lung. Cell-adhesion proteins and extra-cellular matrix proteins constitute the treatment targets. According to the invention, a biological or biotechnological system is brought into contact with a dissolved substance that has an affinity to at least one of the following genes: ADAM19, Mmp12, Col18a1, Col15a1, CD44, Bsg, Itgb2, Itgax, Lamc2, Lamb3, Alcam, Cldn2, Cldn3, Cldn7, Krt1-18, Krt2-8, tacstd1, tacstd2, S100a1, S100a11, their variants, parts of said genes, their mRNA or their gene products, cleavage products derived from said genes, polypeptides or peptides, said substance being bound to a suitable marker. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009118205-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9068230-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010121231-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2105740-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9617600-B2 |
| priorityDate | 2005-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 676.